Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LYEL Lyell Immunopharma Inc
- Stocks
- Healthcare
- NASDAQ: LYEL
Price (delayed)
$9.74
Market cap
$143.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25
Enterprise value
$70.66M
Highlights
Lyell Immunopharma's debt has decreased by 11% YoY and by 4.2% QoQ
LYEL's quick ratio has dropped by 55% year-on-year but it is up by 6% since the previous quarter
The net income has declined by 47% year-on-year but it rose by 2.5% since the previous quarter
Lyell Immunopharma's equity has decreased by 44% YoY and by 12% from the previous quarter
The gross profit has contracted by 11% YoY and by 4.9% from the previous quarter
Key stats
What are the main financial stats of LYEL
Market
Valuations
Earnings
Shares outstanding
14.77M
Market cap
$143.83M
Enterprise value
$70.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
2,477.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,218.35
Revenue
$58,000
Gross profit
$58,000
Operating income
-$360.55M
Net income
-$334.52M
EBIT
-$334.52M
EBITDA
-$316.47M
Free cash flow
-$175.8M
Per share
Balance sheet
Liquidity
EPS
-$25
EPS diluted
-$25
Free cash flow per share
-$11.91
Book value per share
$22.8
Revenue per share
$0
TBVPS
$29.13
Total assets
$429.8M
Total liabilities
$93.28M
Debt
$48.85M
Equity
$336.52M
Working capital
$267.89M
Debt to equity
0.15
Current ratio
7.49
Quick ratio
7.34
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-545,644.8%
Gross margin
100%
Net margin
-576,762.1%
Operating margin
-621,644.8%
Return on assets
-61%
Return on equity
-73.7%
Return on invested capital
-75.4%
Return on capital employed
-86.1%
Return on sales
-576,762.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYEL stock price
How has the Lyell Immunopharma stock price performed over time
Intraday
0%
1 week
-23.67%
1 month
20.4%
1 year
-81.2%
YTD
-23.91%
QTD
-9.48%
Financial performance
How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$58,000
Gross profit
$58,000
Operating income
-$360.55M
Net income
-$334.52M
Gross margin
100%
Net margin
-576,762.1%
The operating margin has dropped by 68% year-on-year and by 6% since the previous quarter
Lyell Immunopharma's net margin has shrunk by 64% YoY and by 2.6% QoQ
The operating income has dropped by 50% year-on-year
The net income has declined by 47% year-on-year but it rose by 2.5% since the previous quarter
Price vs fundamentals
How does LYEL's price correlate with its fundamentals
Growth
What is Lyell Immunopharma's growth rate over time
Valuation
What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.43
P/S
2,477.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,218.35
The EPS has declined by 39% year-on-year but it rose by 4.6% since the previous quarter
The stock's P/B is 69% less than its 5-year quarterly average of 1.4 and 28% less than its last 4 quarters average of 0.6
Lyell Immunopharma's equity has decreased by 44% YoY and by 12% from the previous quarter
LYEL's price to sales (P/S) is 47% less than its last 4 quarters average of 4659.3 but 24% more than its 5-year quarterly average of 1993.9
The revenue has declined by 11% year-on-year and by 4.9% since the previous quarter
Efficiency
How efficient is Lyell Immunopharma business performance
The ROE has plunged by 117% YoY and by 12% from the previous quarter
The ROA has dropped by 105% year-on-year and by 9% since the previous quarter
Lyell Immunopharma's ROIC has plunged by 97% YoY and by 13% from the previous quarter
The return on sales has dropped by 64% year-on-year and by 2.6% since the previous quarter
Dividends
What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYEL.
Financial health
How did Lyell Immunopharma financials performed over time
The current ratio has dropped by 55% year-on-year but it rose by 6% since the previous quarter
LYEL's quick ratio has dropped by 55% year-on-year but it is up by 6% since the previous quarter
Lyell Immunopharma's debt is 85% lower than its equity
The debt to equity has surged by 67% year-on-year and by 15% since the previous quarter
Lyell Immunopharma's equity has decreased by 44% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.